PHILADELPHIA and LONDON, July 15 /PRNewswire/ -- Thomson Reuters today announced a partnership agreement with Sagient Research, a leading provider of biopharmaceutical institutional research. Thomson Reuters will incorporate Sagient's assessments, forecasts and approval timelines on clinical-stage drugs into the upcoming Forecast Module of Thomson Pharma(R) Partnering.
The Forecast Module, in beta testing now and planned for release in the fourth quarter, will integrate Sagient's data with comprehensive scientific and commercial analysis of the industry pipeline from Thomson Reuters, providing a combination of data to help biopharma companies and investors assess new drugs. The product will be the first on the market to put forecasting tools together with deep intelligence on the industry pipeline, enabling quicker, higher quality sales forecasts. It will provide ratings of the likelihood of drug approvals, monitor upcoming events that will affect those approvals, and provide multiple perspectives on sales forecasts, including downloadable Excel models that allow customers to tailor with their own assumptions.
"With increasing licensing activity and more scrutiny on drug development, our customers need to assess sales potential of new drugs more often than ever before," said Jon Brett-Harris, EVP of Life Sciences, Thomson Reuters. "The partnership with Sagient is an important investment in Thomson Pharma Partnering, which will put in a single place all the information required to enable quicker, better partnering and investment decisions."
"We are excited to partner with Thomson Reuters to bring our unique research to a much larger audience," said Brian Overstreet, President & CEO of Sagient Research. "Combining elements of our BioMedTracker content with Thomson Reuters' pipeline and other comm
|SOURCE Thomson Reuters|
Copyright©2009 PR Newswire.
All rights reserved